Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UC CIMZIA
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 10 May 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017.